Stage III NSCLC: Practical Application of Immune Checkpoint Inhibition After Chemoradiotherapy
The goal of this activity is to improve participants’ knowledge of and competence in applying immune checkpoint inhibitors in the treatment of patients with stage III NSCLC.
Jointly provided by NCCN and Clinical Care Options, LLC.
This program is intended for physicians, nurses, pharmacists, and other healthcare providers who care for patients with stage III non-small-cell lung cancer.
Upon completion of this activity, participants should be able to:
- Discuss the biologic rationale for using immune checkpoint inhibitors in patients with locally advanced NSCLC.
- Plan optimal, individualized therapeutic strategies for patients with stage III NSCLC, considering the available clinical evidence, expert recommendations, and patient preferences.
- Identify subsets of patients most likely to benefit from durvalumab consolidation after definitive platinum-based chemotherapy and concurrent radiation therapy.
- Assess and manage immune-mediated adverse events experienced by patients receiving immune checkpoint inhibitors.
- Explain the benefits and risks of using immune checkpoint inhibitor therapy to patients with unresectable stage III NSCLC.
Matthew Gubens, MD, MS
Associate Professor Thoracic Oncology
University of California, San Francisco
San Francisco, California
Leora Horn, MD, MSc, FRCPC
Associate Professor of Medicine
Clinical Director, Thoracic Oncology Research Program
Assistant Vice Chairman for Faculty Development
Vanderbilt Ingram Cancer Center
Karen L. Reckamp, MD, MS
Professor Medical Oncology and Therapeutics Research
City of Hope Comprehensive Cancer Center
Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics.
The faculty and CCO staff reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity.
Matthew Gubens, MD, MS, has disclosed that he has received consulting fees from AstraZeneca, Bristol-Myers Squibb, Genentech/Roche, Mersana Therapeutics, and Novartis and funds for research support paid to his institution from Merck and OncoMed.
Leora Horn, MD, MSc, FRCPC, has disclosed that she has received consulting fees from AbbVie, AstraZeneca, Bristol-Myers Squibb, Genentech, Lilly, Merck, and Xcovery and funds for research support from Boehringer Ingelheim and Xcovery.
Karen L. Reckamp, MD, MS, has disclosed that she has received consulting fees from Amgen, Astellas, Euclises, Takeda/Ariad, and Tesaro and funds for research support from AbbVie, ACEA, Adaptimmune, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, Guardant Health, Loxo Oncology, Novartis, Pfizer, Seattle Genetics, Takeda/Ariad, and Xcovery.
The activity planning staff listed below has no relevant financial relationships to disclose:
Timothy Quill, PhD; Megan Cartwright, PhD; Rachael M. Andrie, PhD; Kevin Obholz, PhD
Kimberly Bayer; Melissa Esplen; Mark A. Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Rashmi Kumar, PhD; Heather Matt; Joan S. McClure, MS; Diane McPherson; Melanie Moletzsky; Lisa Perfidio, MS; Liz Rieder; Shannon Ryan; Kathy Ann Smith, CMP, CHCP; Melinda Somasekhar, PhD (employed by NCCN until October 30, 2017)
The NCCN Activity Planning staff listed below discloses the following relevant financial relationships:
Donald Harting, ELS, CHCP, has disclosed that he has equity interest/stock options from Laboratory Corporation of America (LabCorp).
Katherine Pierce has disclosed that she has equity interest/stock options from Boston Scientific Corporation and Pfizer Inc.
The NCCN clinical information team listed below, who have reviewed content, have no relevant financial relationships to disclose:
Miranda Hughes, PhD
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. National Comprehensive Cancer Network® (NCCN®) and Clinical Care Options, LLC, do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of NCCN and Clinical Care Options, LLC. Please refer to the official prescribing information for each product for discussion of approved indication, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of National Comprehensive Cancer Network (NCCN) and Clinical Care Options, LLC. NCCN is accredited by the ACCME to provide continuing medical education for physicians.
NCCN designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 1.0 hour of Category 1 credit for completing this activity.
National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
NCCN designates this educational activity for a maximum of 0.88 contact hours.
|National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.|
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: 0836-9999-18-031-H01-P
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 0.88 ANCC contact hours
- 1.00 Participation